



**SHATTUCK**  
LABS

NEWS RELEASE

# Shattuck Labs to Report Fourth-Quarter and Full-Year 2022 Financial Results on February 23, 2023

2023-02-16

AUSTIN, TX & DURHAM, NC, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will report its fourth quarter and full year 2022 financial results and provide a general business overview on Thursday, February 23, 2023.

**Title:** Shattuck Labs Fourth-Quarter and Full-Year 2022 Earnings Conference Call

**Speakers:** Taylor Schreiber, *CEO*; Andrew Neill, *CFO*; Lini Pandite, *CMO*

**Date & Time:** Thursday, February 23, 2023 at 4:45 p.m. ET

**Dial-in Details:** Toll-Free Dial-In Number: (888) 440-4368

Toll Dial-In Number: (646) 960-0856

Conference ID: 5023003

**Webcast Details:** <https://events.q4inc.com/attendee/940317356>

To listen to the live webcast, please visit the Investor Relations page of the Shattuck Labs website [here](#). Participants may register for the call [here](#). While not required, interested participants are encouraged to join 10 minutes prior to the start of the event.

A replay of the webcast will be available following the conclusion of the live call and will be accessible on the Company's website.

## **About Shattuck Labs, Inc.**

Shattuck Labs, Inc. (NASDAQ: STTK) is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck's proprietary Agonist Redirected Checkpoint, ARC®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules with a single therapeutic. The company's lead SL-172154 (SIRPα-Fc-CD40L) program, which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in multiple Phase 1 trials. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both

Austin, Texas and Durham, North Carolina. For more information, please visit: [www.ShattuckLabs.com](http://www.ShattuckLabs.com).

The Company intends to use the investor relations portion of its website as a means of disclosing material non-public information and for complying with disclosure obligations under Regulation FD.

**Investor & Media Contact:**

Conor Richardson  
Vice President of Investor Relations  
Shattuck Labs, Inc.  
[InvestorRelations@shattucklabs.com](mailto:InvestorRelations@shattucklabs.com)

Source: Shattuck Labs, Inc.